Only limited prior maternal safety data have specifically focused on BRCA carriers conceiving after breast cancer
Tamoxifen protected against contralateral breast cancer for carriers of BRCA1 mutations (odds ratio 0·38, 95% Cl 0·19–0·74) and for those with BRCA2 mutations (0·63, 0·20–1·50)
56) but not in BRCA1 carriers (RR 1
Our recent study showed a small but non-significant benefit of tamoxifen in primary prevention of breast cancer in BRCA1 and BRCA2 carriers [ 32 ]
Since autonomy of choice
Tamoxifen is a medication that some BRCA carriers elect to take in order to reduce their risk of breast cancer